← Back to Analyst Consensus 
CRBP Buy
Corbus Pharmaceuticals Holdings, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 7, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Aug 7, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 23, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 17, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| May 27, 2026 | Wedbush | maintain | Outperform → Outperform | — | 57% |
| May 26, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 22, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| May 13, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| May 13, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| May 13, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Apr 29, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Mar 10, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Nov 13, 2025 | RBC Capital | maintain | Outperform → Outperform | $53 | 55% |
| Oct 20, 2025 | Wedbush | maintain | Outperform → Outperform | $38 | 57% |
| Oct 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Sep 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Aug 6, 2025 | Oppenheimer | maintain | Outperform → Outperform | $53 | 52% |
| May 7, 2025 | RBC Capital | maintain | Outperform → Outperform | $58 | 55% |
| May 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $56 | 52% |
| May 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Mar 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Mar 11, 2025 | Jefferies | maintain | Buy → Buy | $53 | 52% |
| Feb 28, 2025 | William Blair | initiate | — → Outperform | $0 | 47% |
| Feb 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Feb 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Dec 2, 2024 | Piper Sandler | initiate | — → Overweight | $35 | 54% |
| Aug 7, 2024 | RBC Capital | reiterate | Outperform → Outperform | $82 | 55% |
| Aug 7, 2024 | Oppenheimer | maintain | Outperform → Outperform | $88 | 52% |
| Aug 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Jul 10, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $80 | 52% |
| Jun 26, 2024 | B. Riley Securities | initiate | — → Buy | $85 | 54% |
| Jun 11, 2024 | RBC Capital | maintain | Outperform → Outperform | $82 | 55% |
| Jun 3, 2024 | Oppenheimer | maintain | Outperform → Outperform | $80 | 52% |
| May 13, 2024 | RBC Capital | initiate | — → Outperform | $77 | 55% |
| May 8, 2024 | Oppenheimer | maintain | Outperform → Outperform | $60 | 52% |
| Mar 13, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $58 | 52% |
| Mar 6, 2024 | Jefferies | upgrade | Hold → Buy | $46 | 52% |
| Jan 29, 2024 | Oppenheimer | maintain | Outperform → Outperform | $51 | 52% |
| Aug 9, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $22 | 52% |
| May 10, 2023 | Oppenheimer | upgrade | Perform → Outperform | $22 | 52% |
| Mar 8, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $3 | 44% |
Price Target Trend
Apr 26, 2026 Latest: $35.89 Oct 26, 2026
EPS Estimates
+1y $-5.51
Lo: $-6.90 Hi: $-2.97
9 analysts ▲4
0y $-5.43
Lo: $-6.81 Hi: $-4.06
10 analysts +1q $-1.32
Lo: $-1.74 Hi: $-0.74
10 analysts ▲2
0q $-1.21
Lo: $-1.91 Hi: $-0.73
10 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days